ABBV vs ABT
AbbVie Inc. vs Abbott Laboratories · Updated Jun 28, 2026
ABBV — 13 winsABT — 10 wins
Price Performance
ABBV +36.49%ABT -30.80%
Performance
| ABBV | ABT | |
|---|---|---|
| 1 Month | +15.01% | +8.85% |
| 3 Months | +17.34% | -10.82% |
| 6 Months | +8.28% | -25.51% |
| YTD | +8.42% | -25.56% |
| 1 Year | +33.63% | -32.46% |
| 3 Year | +81.01% | -12.60% |
| 5 Year | +119.00% | -16.46% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | +10.5% | +27.3% | +11.2% | -4.6% | +19.3% | +28.4% | +19.6% | -0.8% | -6.3% | +55.0% | +8.7% | -10.1% |
| ABT | -24.2% | +10.4% | +3.0% | +0.5% | -21.0% | +29.0% | +25.9% | +25.0% | +23.0% | +46.1% | -10.5% | +0.0% |
Valuation
| ABBV | ABT | |
|---|---|---|
| P/E Ratio | 121.48 | 25.98 |
| Forward P/E | 15.20 | 16.13 |
| PEG Ratio | 7.45 | 2.32 |
| P/S Ratio | 6.47 | 3.39 |
| P/B Ratio | 14.78 | 2.31 |
| EV/EBITDA | 30.01 | 17.01 |
Financials
| ABBV | ABT | |
|---|---|---|
| EPS (TTM) | $2.04 | $3.59 |
| Gross Margin | +83.54% | +56.28% |
| Operating Margin | +31.56% | +16.50% |
| Net Margin | +4.66% | +9.65% |
| ROE | +13.23% | +9.50% |
| ROA | +2.67% | +5.07% |
| Debt/Equity | 2.65 | 0.52 |
Growth
| ABBV | ABT | |
|---|---|---|
| Revenue Growth YoY | +12.43% | +7.78% |
| Revenue Growth QoQ | -9.72% | -2.57% |
| EPS Growth YoY | -45.83% | -18.24% |
| EPS Growth QoQ | -61.76% | -39.22% |
Technical
| ABBV | ABT | |
|---|---|---|
| RSI (14) | 77.06 | 67.29 |
| % From 20-Day SMA | +9.63% | +4.18% |
| % From 50-Day SMA | +15.34% | +4.63% |
| % From 200-Day SMA | +11.97% | -17.26% |
| % From 52-Week High | -2.22% | -32.83% |
| % From 52-Week Low | +36.32% | +13.77% |
Analyst Ratings
ABBV
Buy(19 analysts)
Strong SellHoldStrong Buy
Price Target
$258.00
+4.15% upside
ABT
Buy(29 analysts)
Strong SellHoldStrong Buy
Price Target
$126.00
+35.11% upside
Overview
| ABBV | ABT | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Devices |
| Exchange | NYSE | NYSE |
| Market Cap | $406.47B | $152.89B |
| Shares Outstanding | 1.77B | 1.74B |
| Avg Volume (10D) | 11.82M | 16.32M |
| Dividend Yield | 2.93% | 2.78% |
Frequently Asked Questions
Is ABBV or ABT a better buy right now?
Based on 23 comparable metrics, ABBV leads in 13 categories while ABT leads in 10. ABBV has a consensus analyst rating with 19 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, ABBV or ABT?
Over the past year, ABBV returned +33.63% compared to ABT's -32.46%. In the short term (1 month), ABBV returned +15.01% vs ABT's +8.85%.
Is ABBV or ABT more expensive?
ABBV trades at a P/E of 121.48 compared to ABT's 25.98. On a price-to-sales basis, ABBV trades at 6.47x vs ABT's 3.39x. Forward P/E: ABBV at 15.20 vs ABT at 16.13.
Which stock has higher growth, ABBV or ABT?
ABBV's revenue grew +12.43% year-over-year compared to ABT's +7.78%. EPS growth: ABBV at -45.83% vs ABT at -18.24%.
Do ABBV and ABT pay dividends?
ABBV pays a dividend with a yield of 2.93%. ABT pays a dividend with a yield of 2.78%.
Which stock do analysts prefer, ABBV or ABT?
ABBV has 19 analysts with a target price of $258.00 (+4.15% upside). ABT has 29 analysts with a target of $126.00 (+35.11% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.